Cipla Ltd. on Friday said the U.S. District Court of Delaware has denied Amgen Inc's request for preliminary injunction to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets in the U.S. market.
Preliminary injunction is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order to preserve the status quo until the trial is over and the court has issued a ruling or judgment.
Cipla had announced a phased launch of generic cinacalcet hydrochloride tablets, used in the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, in the U.S. market in a regulatory filing in March this year. The launch, however, is a subject of ongoing litigation, it had added.
"... Chief Judge Stark of the U.S. District Court of Delaware denied Amgen Inc's request for preliminary injunction to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets 30 mg, 60 mg, 90 mg in the U.S.A.," Cipla said in a filing to Bombay Stock Exchange.
Cipla's cinacalcet hydrochloride tablets in the strengths of 30 mg, 60 mg and 90 mg are generic versions of Sensipar, a branded drug marketed by Amgen Inc.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
